Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: a progress report.

Abstract

Medical and Pediatric OncologyVolume 40, Issue 1 p. 66-69 International NoteFree Access Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: A progress report T.G. Sagar MD, DM, Corresponding Author T.G. Sagar MD, DM [email protected] Department of Medical Oncology (Clinical), Cancer Institute (W.I.A), Chennai, IndiaCancer Institute (W.I.A), 18, Sardar Patel Road, Chennai-600 036, India.Search for more papers by this authorAnita Chandra MD, Dip NB, DM, Anita Chandra MD, Dip NB, DM Department of Medical Oncology (Clinical), Cancer Institute (W.I.A), Chennai, IndiaSearch for more papers by this authorS.G. Raman MD, DM, S.G. Raman MD, DM Department of Medical Oncology (Clinical), Cancer Institute (W.I.A), Chennai, IndiaSearch for more papers by this author T.G. Sagar MD, DM, Corresponding Author T.G. Sagar MD, DM [email protected] Department of Medical Oncology (Clinical), Cancer Institute (W.I.A), Chennai, IndiaCancer Institute (W.I.A), 18, Sardar Patel Road, Chennai-600 036, India.Search for more papers by this authorAnita Chandra MD, Dip NB, DM, Anita Chandra MD, Dip NB, DM Department of Medical Oncology (Clinical), Cancer Institute (W.I.A), Chennai, IndiaSearch for more papers by this authorS.G. Raman MD, DM, S.G. Raman MD, DM Department of Medical Oncology (Clinical), Cancer Institute (W.I.A), Chennai, IndiaSearch for more papers by this author First published: 07 November 2002 https://doi.org/10.1002/mpo.10017Citations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Buyukpamukcu M, Atahan L, Caglar M, et al. Hodgkin disease in Turkish children: clinical characteristics and treatment results of 210 patients. Pediatr Hematol Oncol 1999; 16: 119– 129. 2 Shanta V, Sastri DVLN, Sagar TG, et al. A review of Hodgkin disease at the Cancer Institute, Madras. Clin Oncol 1982; 8: 5– 15. 3 Lobo Sanahuja F, Garcia I, Barrantes JC, et al. Pediatric Hodgkins disease in Costa Rica: twelve years experience of primary treatment by chemotherapy alone, without staging laparotomy. Med Pediatr Oncol 1994; 22: 398– 403. 4 Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin disease. Cancer Res 1996; 26: 1063. 5 Carbone PP, Kalpan HS, Musshoff K, et al. Report of the committee on Hodgkin disease staging classification. Cancer Res 1971; 31: 1860– 1861. 6 Montoto S, Camos M, Lopez-Guillermo A, et al. Hybrid chemotherapy, consisting of cyclophosphamide, vincristine, procarbazine, prednisolone, doxorubcin, bleomycin and vinblastine (C—MOPP/ABV) as first line treatment for patients with advanced Hodgkin disease. Cancer 2000; 88: 2142– 2148. 7 Kaplan GL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457– 463. 8 Peto R, Pike MC. Conversion of the S(0−E)2/E in the log rank test for survival data on tumor incidence data. Biometrics 1973; 29: 579– 584. 9 Sripada PV, Tenali SG, Vasudevan M, et al. Hybrid (COPP/ABV) therapy in childhood. Hodgkin disease a study of 53 cases during 1989–1993 at Cancer Institute, Madras. Pediat Haematol Oncol 1995; 12: 333– 341. 10 Shankar AG, Ashley S, Radford M, et al. Does histology influence outcome in childhood Hodgkin disease? Results from the United Kingdom Children's Cancer Study group. J Clin Oncol 1997; 15: 2622– 2630. 11 Schellong G. Pediatric Hodgkin disease treatment in the late 1990s. Ann Oncol 1998; 9: 115– 119. 12 Wolf J, Engert A, Diehl V. Issue in the treatment of Hodgkin disease. Curr Opin Oncol 1998; 10: 396– 402. 13 Oberlin O, Leverger G, Pacquement MA, et al. Low dose radiation therapy and reduced chemotherapy in childhood Hodgkin disease. The experience of the French Society of Pediatric Oncology. J Clin Oncol 1992; 10: 1602. 14 Andrieu JM, Ifrah N, Payen C, et al. Increased risk of second acute non lymphocytic leukemia after extended field radiation therapy combined with MOPP chemotherapy for Hodgkin disease. J Clin Oncol 1990; 8: 1148– 1154. 15 Schellong G, Riepenhausen M, Creutzig U, et al. Low risk of secondary leukemia after chemotherapy without mechlorethamine in childhood Hodgkin disease German–Austrian Pediatric Hodgkin Disease Group. J Clin Oncol 1997; 15: 2247– 2253. Citing Literature Volume40, Issue1January 2003Pages 66-69 ReferencesRelatedInformation